Every material Form 8-K ANGIODYNAMICS INC has filed with the SEC since July 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AngioDynamics reported fiscal first-quarter 2027 net sales of $80.9 million, up 6.9%, and a GAAP net loss of $7.1 million, or $0.17 per share, versus a loss of $10.9 million a year earlier. The company also said Eric Honroth will succeed Jim Clemmer as President and CEO on November 2, 2026, and reiterated its fiscal 2027 guidance, which matters to shareholders because it signals continuity in results and a planned leadership change.
Net sales were $80.9 million, up 6.9%; Med Tech sales rose 13.2% to $39.9 million while Med Device sales rose 1.4% to $41.0 million.
GAAP net loss narrowed to $7.1 million, or $0.17 per share, from $10.9 million, or $0.26 per share, a year earlier.
Adjusted EBITDA was $5.0 million versus $2.2 million; gross margin was 59.4%, including $1.2 million of tariff refunds.
Eric Honroth becomes CEO effective November 2, 2026, succeeding Jim Clemmer; fiscal 2027 net sales guidance of $336.0 million to $341.0 million was reiterated.
AngioDynamics said Eric Honroth will become President and Chief Executive Officer and a director effective November 2, 2026, succeeding James Clemmer, who has led the company since April 2016 and is retiring. The filing also sets Honroth's pay, including a $735,000 base salary and a $350,000 sign-on bonus, and a $30,000 monthly consulting arrangement for Clemmer for one year.
Eric Honroth, 55, most recently served as President Life Science at Getinge AB from 2018 to 2026.
Honroth's base salary is $735,000, with a target annual bonus of 95% of base salary.
Honroth receives a $350,000 cash sign-on bonus, repayable if he leaves without Good Reason or is terminated for Cause within the first year.
Clemmer will consult for the company for one year at $30,000 per month; Howard Donnelly plans to retire as a Class II director at the end of his current term.
AngioDynamics reported fiscal 2026 results for the year ended May 31, 2026, with pro forma net sales up 9.4% to $320.2 million and Med Tech sales up 18.4% to $150.0 million. The GAAP net loss widened to $36.7 million, or $0.88 per share, from $34.0 million, or $0.83, a year earlier, and the company issued fiscal 2027 guidance calling for net sales of $336.0 million to $341.0 million and adjusted loss per share of $0.29 to $0.24.
Fourth-quarter pro forma net sales were $86.6 million, up 8.0%, but the GAAP loss per share was $0.27 versus $0.15 a year earlier.
Full-year adjusted EBITDA was $13.2 million, compared with $7.6 million in the prior year.
Fiscal 2027 guidance: net sales of $336.0 million to $341.0 million and adjusted EPS of ($0.29) to ($0.24), compared with fiscal 2026 adjusted loss per share of $0.24.
The company ended fiscal 2026 with $53.9 million in cash and states it has a debt-free balance sheet.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ANGIODYNAMICS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →